Modulation of cardiac remodeling by adenosine: In vitro and in vivo effects

Molecular and Cellular Biochemistry

Volumn 251, Issue 1-2, 2003, Pages 17-26

  Villarreal, Francisco ^a   Zimmermann, Scott ^a   Makhsudova, Lala ^a   Montag, Annika C ^a   Erion, Mark D ^a   Bullough, David A ^a   Ito, Bruce R ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

Adenosine; Cardiac remodeling; Myocardial infarction

Indexed keywords

2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 4 AMINO 3 BROMOPYRAZOLO[3,4 D]PYRIMIDINE 1 (5 AMINO 5 DEOXYRIBOSIDE); 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; ADENOSINE DERIVATIVE; ADENOSINE KINASE; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR STIMULATING AGENT; AUTACOID; CATECHOLAMINE; CELL SURFACE RECEPTOR; CYCLIC AMP; DILAZEP; DIPYRIDAMOLE; DRAFLAZINE; FIBRINOLYTIC AGENT; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOVASCULAR SYSTEM; CATECHOLAMINE RELEASE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE RELEASE; DOSE RESPONSE; ENZYME INHIBITION; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART MUSCLE REPERFUSION; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOSIDE TRANSPORT; PURINE METABOLISM; REGULATORY MECHANISM;

ADENOSINE; ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RECEPTORS, PURINERGIC P1; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 0141728528     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025401026441     Document Type: Article

References (64)

1. Feoktistov I, Biaggioni I: Adenosine A2B receptors. Pharm Rev 49: 381-402, 1997
2. Mullane K, Bullough D: Harnessing an endogenous cardioprotective mechanism: Cellular sources and sites of action of adenosine. J Mol Cell Cardiol 27: 1041-1054, 1995
3. Schrader J, Decking U: Adenosine metabolism, transport, and energetics. Drug Dev Res 45: 288-294, 1998
4. Dubey R, Gillespie D, Mi Z, Jackson E: Cardiac fibroblasts metabolize cyclic-AMP to generate adenosine. Hypertension 28: 7, 1996
5. Olsson R: Adenosine receptors in the cardiovascular system. Drug Dev Res 39: 301-307, 1996
6. Olsson R, Pearson J: Cardiovascular purinoceptors. Phys Rev 70: 761-845, 1990
7. Elfman L, Lindgren E, Walum E, Fredholm B: Adenosine analogues stimulate cyclic AMP-accumulation in cultured neuroblastoma and glioma cells. Acta Pharma Toxicol 55: 297-302, 1984
8. Feoktistov I, Biaggioni I: Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96: 1979-86, 1995
9. Marquardt D, Walker L, Heinemann S: Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J Immunol 152: 4508-4515, 1994
10. Webb R, Sills M, Chovan J, Balwierczak J, Francis J: CGS 21680: A potent selective adenosine A2 receptor agonist. Cardiovasc Drug Rev 10: 26-53, 1992
11. Liang B, Haltiwanger B: Adenosine A2a and A2b receptors in cultured fetal chick heart cells. High- and low-affinity coupling to stimulation of myocyte contractility and cAMP accumulation. Circ Res 76: 242-251, 1995
12. Stein B, Mende U, Neumann J, Schmitz W, Scholz H: Pertussis toxin unmasks stimulatory myocardial A2-adenosine receptors on ventricular cardiomyocytes. J Mol Cell Cardiol 25: 655-659, 1993
13. Xu H, Stein B, Liang B: Characterization of a stimulatory adenosine A2a receptor in adult rat ventricular myocyte. Am J Physiol 270: H1655-H1661, 1996
14. Dubey R, Gillespie D, Osaka K, Suzuki F, Jackson E: Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2b receptor. Hypertension, 27: 786-793, 1996
15. Boyle D, Sajjadi F, Firestein G: Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthr Rheum 39: 923-930, 1996
16. Tucker A, Linden J: Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 27: 62-67, 1993
17. Kitakaze M, Hori M: Adenosine therapy: A new approach to chronic heart failure. Exp Opin Invest Drugs 9: 2519-2535, 2000
18. Sommerschild H, Kirkeboen K: Adenosine and cardioprotection during ischaemia and reperfusion - an overview. Acta Anaesthesiol Scand 44: 1038-1055, 2000
19. Pitarys C, Virmani R, Vildibill H, Jackson E, Forman M: Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 83: 237-247, 1991
20. Todd J, Zhao Z, Williams M, Sato H, Van Wylen D, Vinten-Johansen J: Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence. Ann Thorac Surg 62: 1364-1372, 1996
21. Zhao,Z, Nakamura M, Wang N, Wilcox J, Shearer S, Guyton R, Vinten-Johansen J: Administration of adenosine during reperfusion reduces injury of vascular endothelium and death of myocytes. Coron Artery Dis 10: 617-628, 1999
22. Vander Heide R, Reimer K: Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 31: 711-718, 1996
23. Baxter G, Hale S, Miki T, Kloner R, Cohen M, Downey J, Yellon D: Adenosine A1 agonist at reperfusion trial (AART): Results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 14: 607-614, 2000
24. Sekili S, Jeroudi M, Tang X, Zughaib M, Sun J, Bolli R: Effect of adenosine on myocardial 'stunning' in the dog. Circ Res 76: 82-94, 1995
25. Garratt K, Holmes D, Molina Viamonte V, Reeder G, Hodge D, Bailey K, Lobl J, Laudon D, Gibbons R: Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J 136: 196-204, 1998
26. Mahaffey K, Puma J, Barbagelata N, DiCarli M, Leesar M, Browne K, Eisenberg P, Bolli R, Casas A, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons, R Califf R, Granger C: Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol 34: 1711-1720, 1999
27. Marzilli M, Orsini E, Marraccini P, Testa R: Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101: 2154-2159, 2000
28. Nees S, Herzog V, Becker B, Bock M, Des Rosiers C, Gerlach E: The coronary endothelium: A highly active metabolic barrier for adenosine. Basic Res Cardiol 80: 515-529, 1985
29. Sparks H, Bardenheuer H: Regulation of adenosine formation by the heart. Circ Res 58: 193-201, 1986
30. Martin B, McClanahan T, Van Wylen D, Gallagher K: Effects of ischemia, preconditioning, and adenosine deaminase inhibition on interstitial adenosine levels and infarct size. Basic Res Cardiol 92: 240-251, 1997
31. Zughaib M, Abd-Elfattah A, Jeroudi M, Sun J, Sekili S, Tang X, Bolli R: Augmentation of endogenous adenosine attenuates myocardial 'stunning' independently of coronary flow or hemodynamic effects. Circulation 88: 2359-2369, 1993
32. Abd-Elfattah A, Jessen M, Wechsler A: Nucleoside trapping during reperfusion prevents ventricular dysfunction, 'stunning,' in absence of adenosine. Possible separation between ischemic and reperfusion injury. J Thorac Cardiovasc Surg 108: 269-278, 1994
33. Strauer B, Heidland U, Heintzen M, Schwartzkopff B: Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol 28: 1119-1126, 1996
34. Heidland U, Heintzen M, Michel C, Strauer B: Intracoronary administration of dipyridamole prior to percutaneous transluminal coronary angioplasty provides a protective effect exceeding that of ischemic preconditioning. Coron Artery Dis 11: 607-613, 2000
35. Andersen K, Dellborg M, Swedberg K: Nucleoside transport inhibition by draflazine in unstable coronary disease. Eur J Clin Pharmacol 51: 7-13, 1996
36. Mangano D: Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Jama 277: 325-332, 1997
37. Pfeffer M, Braunwald E: Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161-1172, 1990
38. Boyle M, Weisman H: Limitation of infarct expansion and ventricular remodeling by late reperfusion. Study of time course and mechanism in a rat model. Circulation 88: 2872-2883, 1993
39. Kroll K, Decking UK, Dreikorn K, Schrader J: Rapid turnover of the AMP-adenosine metabolic cycle in the guinea pig heart. Circ Res 73: 846-856, 1993
40. Wagner D, Bontemps F, van den Berghe G: Existence and role of substrate cycling between AMP and adenosine in isolated rabbit cardiomyocytes under control conditions and in ATP depletion. Circulation 90: 1343-1349, 1994
41. Ugarkar B, DaRe J, Kopcho J, Browne C, Schanzer J, Wiesner J, Erion M: Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. J Med Chem 43: 2883-2893, 2000
42. Firestein G, Boyle, D, Bullough D, Gruber H, Sajjadi F, Montag A, Sambol B, Mullane K: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 152: 5853-5859, 1994
43. Bauer, Bouma M, Herrmann I, van den Wildenberg F, Firestein G, Marzi I, Buurman W: Adenosine kinase inhibitor GP515 attenuates hepatic leukocyte adhesion after hemorrhagic hypotension. Am J Physiol 273: G1297-G1303, 1997
44. Alhaddad I, Kazimuddin M, Brown E: Late coronary artery reperfusion: Benefits and mechanisms. Can J Cardiol 16: 463-466, 2000
45. Olafsson B, Forman M, Puett D, Pou A, Cates C, Friesinger G, Virmani R: Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and the no- reflow phenomenon. Circulation 76: 1135-1145, 1987
46. Ito H, Maruyama A, Iwakura. K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T: Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93: 223-228, 1996
47. Weber K: Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation 96: 4065-4082, 1997
48. Villarreal F, Kim N: Modulation of cardiac fibroblast function by growth factors and mechanical stimuli. Cardiovasc Pathol 7:145-151, 1998
49. Brackett L, Daly J: Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. Biochem Pharm 4: 801-814, 1994
50. Berg R, Moss J, Baum B, Crystal R: Regulation of collagen production by the beta-adrenergic system. J Clin Invest 67: 1457-1462, 1981
51. Kim N, Villegas S, Summerour S, Villarreal F: Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J Mol Cell Cardiol 31: 457-466, 1999
52. Dubey R, Gillespie D, Mi Z, Jackson E: Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: Role of A2B receptors. Circulation 96: 2656-2666, 1997
53. Dubey R, Gillespie D, Jackson E: Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: Role of A2B receptors. Hypertension 1: 943-994, 1998
54. Kovacs E, DiPietro L: Fibrogenic cytokines and connective tissue production. Faseb J 8: 854-861, 1994
55. Witte M, Barbul A: General principles of wound healing. Surg Clin North Am 77: 509-528 1997
56. Meldrum D: Tumor necrosis factor in the heart. Am J Phys, 274: R577-R595, 1998
57. Basaran Y, Basaran M, Babacan K, Ener B, Okay T, Gök H, Ozdemir M: Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology 44: 332-337, 1993
58. Yue P, Massie B, Simpson P, Long C: Cytokine expression increases in non-myocytes from rats with postinfarction heart failure. Am J Physiol 275: H250-H258, 1998
59. Feldman A, Combes A, Wagner D, Kadakomi T, Kubota T, Li Y, McTiernan, C: The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35: 537-44, 2000
60. Kubota T, McTiernan C, Frye C, Slawson S, Lemster B, Koretsky A, Demetris A, Feldman A: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81: 627-635, 1997
61. Wagner D, Combes A, McTiernan C, Sanders V, Lemster B, Feldman A: Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha. Circ Res 82: 47-56, 1998
62. Wagner D, McTiernan C, Sanders V, Feldman A: Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation 97: 521-524, 1998
63. Loh E, Rebbeck T, Mahoney P, DeNofrio D, Swain J, Holmes E: Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 99: 1422-1425, 1999
64. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M: Plasma adenosine levels increase in patients with chronic heart failure. Circulation 95: 1363-1365, 1997